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Aims Statin pretreatment in patients undergoing cardiac surgery is understood to prevent postoperative atrial fibrillation (AF).
However, this is based on observational and limited randomized trial evidence, resulting in uncertainty about any genuine
anti-arrhythmic benefits of these agents in this setting. We therefore aimed to quantify precisely the association between
statin pretreatment and postoperative AF among patients undergoing cardiac surgery.
Methods
and results
A detailed search of MEDLINE and PubMed databases (1st January 1996 to 31st July 2012) was conducted, followed by a
review of the reference lists of published studies and correspondence with trial investigators to obtain individual–
participant data for meta-analysis. Evidence was combined across prospective, randomized clinical trials that compared
the risk of postoperative AF among individuals randomized to statin pretreatment or placebo/control medication before
elective cardiac surgery. Postoperative AF was defined as episodes of AF lasting≥5 min. Overall, 1105 participants from
11 trials were included; of them, 552 received statin therapy preoperatively. Postoperative AF occurred in 19% of these
participants when compared with 36% of those not treated with statins (odds ratio 0.41, 95% confidence interval
0.31–0.54, P, 0.00001, using a random-effects model). Atrial fibrillation prevention by statin pretreatment was consist-
ent across different subgroups.
Conclusion Short-term statin pretreatment may reduce the risk of postoperative AF among patients undergoing cardiac surgery.
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Introduction
Postoperative atrial fibrillation (AF) following cardiac surgery is
reported to occur in 10–65% of patients,1,2 leading to excess mor-
bidity, longer in-hospital stay, and increased costs.3,4 Although the
pathogenesis of AF after cardiac surgery is believed to be multifactor-
ial, including clinical variables and technical intraoperative factors,3
recent studies have suggested a potential role for inflammation.5– 7
Statins are reported to have ‘pleiotropic’, cholesterol-independent
effects, which may be of clinical relevance in conditions associated
with inflammation.8,9 Evidence suggests that patients previously
receiving statin therapy who undergo cardiac surgery tend to have
a lower incidence of postoperative AF.10,11 However, this is based
on observational data12– 20 and therefore liable to confounding by
factors such as concomitant use of cardiovascular medications,
which may themselves attenuate the risk of AF. Single randomized
trials involving a limited number of participants21– 31 have suggested
a potential benefit for the use of statins in this context, but
were individually underpowered to detect any clinically meaningful
associations.
We therefore sought to provide more reliable evidence than hith-
erto possible, by performing a collaborative individual patient-level
meta-analysis of all relevant randomized controlled trials that had
evaluated the effect of short-term statin pretreatment on post-
operative AF in patients undergoing cardiac surgery.
Methods
Data sources and selection criteria
We searched MEDLINE and PubMed databases (from 1st January 1996
to 31st May 2014), and reviewed cited references from published
studies to identify prospective, randomized trials that compared
the risk of postoperative AF among participants randomized to statin
pretreatment or placebo/control therapy prior to elective cardiac surgery
(Figure 1). The keywords ‘statins’, ‘statin’, ‘atorvastatin’, ‘rosuvastatin’, ‘ceri-
vastatin’, ‘simvastatin’, ‘pravastatin’, ‘lovastatin’, and ‘hydroxymethylglutaryl-
CoA’ were combined with the words ‘cardiac surgery’, ‘bypass surgery’,
‘valvular surgery’, and ‘randomized’ to yield relevant studies. Achievement
of LDL-cholesterol lowering with statin therapy requires 3 weeks;32
thus,wedecided toeliminate studiesusing.3weeksof statinpretreatment
in order to specifically investigate anti-arrhythmic effects of statins possibly
due to early pleiotropic effects and in order to exclude effects of these
drugs mediated by LDL-cholesterol lowering (i.e. more long-term effects
secondary to their well-established atheroprotective properties). The
only exception to this rule was in case of studies that had evaluated the
effect of short-term, intensive dose statin therapy in people already receiv-
ing low-dose statin treatment preoperatively (e.g. the study of Kourliouros
et al.27). We included only those studies that were published in English.
Data collection
Of the 14 clinical trials found to be relevant for this meta-
analysis,21 –31,33 –35 the study of Christenson33 was excluded because
patients in the control and statin arms received 4 weeks of pretreatment
before the operation. The studies conducted by Sun et al.34 and Tamayo
et al.35 were also excluded because they were published in Chinese and
Spanish, respectively. Principal investigators of the remaining 11
studies21 –31 werecontacted forparticipant-level dataon: baselinedemo-
graphic and study characteristics; major clinical and operative features of
the populations studied; pre- and postoperative levels of cardiac
biomarkers (specifically creatine kinase-MB and troponin I), and peri-
operative high-sensitivity C-reactive protein (hs-CRP) levels; and
outcome data on postoperative AF. Each investigator returned a standar-
dized electronic form containing relevant data, which were thoroughly
checked for consistency and accuracy. Any disagreements were resolved
by further correspondence with the investigators. A description of study
design, population characteristics, and treatment protocols has been pre-
viously reported in each original paper of the included studies.21–31
Quality of included studies
Studies were evaluated for the adequacy of allocation concealment and
analysis by intention-to-treat principle, using previously established cri-
teria (such as those described by Altman and Schultz36). We did not
weight studies according to any quality scores, as this practice has been
discouraged in controlled clinical trials.37
End point definition
TheprimaryendpointwaspostoperativeAF, whichwasdefined asoneor
moreof the following: (i) in-hospitalAFepisodes lasting≥5min and regis-
tered by the monitoring system on a rhythm strip or 12-lead ECG or (ii)
any clinical episode of AF requiring intervention for angina or haemo-
dynamic compromise. This definition was in keeping with similar defini-
tions used in other studies.21,26,30,31 The proportion of individuals that
experienced the primary end point was calculated both in treatment
arms (i.e. statin pretreatment vs. no statin pretreatment) and in pre-
specified subgroups (such as those defined according to age, gender,
body mass index, type of operation, on- vs. off-pump surgery, left
Detailed search of MEDLINE using as main terms
statin and cardiac surgery and atrial fibrillation
118 potentially relevant articles
56 citations excluded because they were
commentaries, reviews or study level
meta-analyses
23 citations excluded because they were
not prospective, randomized studies
25 citations excluded because they
ascertained outcomes not relevant to
this meta-analysis
14 prospective randomized studies
2 citations excluded because they were
not in English language
1 citation excluded because it did not
meet inclusion criteria for the meta-
analysis
11 prospective randomized studies
included in the meta-analysis
Figure 1 Details of literature review and study selection.
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ventricular ejection fraction, CRP levels, the presence or absence of sys-
temic hypertension, diabetes mellitus, chronic renal failure, chronic ob-
structive pulmonary disease, previous history of AF, and perioperative
use or otherwise of amiodarone, beta-blockers, or calcium antagonists).
It is noteworthy, however, that there were no data concerning post-
operative AF burden (including frequency and duration of the arrhyth-
mia), nor was there any standardized postoperative rhythm-monitoring
strategy across individual studies.
Perioperative myocardial injury was defined as elevation of creatine
kinase-MB .5 times the upper limit of normal (ULN) range or troponin
I .8 times ULN after cardiac surgery;38,39 major adverse cardiovascular
event (MACE) as a composite of acute myocardial infarction, fatal coron-
ary heart disease, coronary revascularization (either percutaneous or
surgical), and fatal or non-fatal ischaemic or haemorrhagic stroke;
in-hospital death as any death occurring during in-patient hospital admis-
sion (regardless of the underlying cause or duration of post-surgery); and
stroke as any focal neurological deficit of acute onset, lasting≥24 h (with
or without further corroboration with brain imaging).
Statistical analysis
Individual patient-level data from each study were harmonized and
reported separately, but subsequently pooled (after weighting for
study size) to reflect the characteristics of the overall cohort. Each
study provided data on the effect of statin pretreatment on the
outcome measures described above using the intention-to-treat ap-
proach. Percentages are presented for discrete variables and mean+
standard deviation or median (with 25th and 75th percentiles) for con-
tinuous variables. Differences between the two treatment groups were
assessed using the Wilcoxon rank-sum test (for continuous traits) or
the x2 test or Fisher’s exact test (for categorical variables). Treatment
effects were estimated as odds ratios (ORs) with 95% confidence inter-
vals (CIs), and subgroup analyses were performed according to pre-
specified study population features.
Individual studies varied considerably and hence a random-effects
model was used to evaluate the effect of statin therapy on various clinical
outcomes, thereby allowing for any between-study differences in treat-
ment that were beyond chance alone. Heterogeneity was formally quan-
tified using the I2 statistic (in turn derived from Cochran’s Q statistic),
which measures the proportion of overall variation in effect estimates
that is attributable to between-study heterogeneity. Potential sources
of heterogeneity were further explored by subgroup analyses and
meta-regression. A two-sided P-value of,0.05 was considered statistic-
ally significant. Analyses were performed using Stata/SE, version 9.2 (Sta-
taCorp, College Station, TX, USA) and Review Manager 4.2.10 software
(available from The Cochrane Collaboration at http//www.cochrane.
org). Details of our study methodology are as stated above, and were
not published previously in any other format (e.g. protocol paper).
Results
Main features of included studies
In total, 1105 participants from 11 randomized controlled trials21– 31
were included in this meta-analysis (552 on statin and 553 on control
treatment). Table 1 summarizes the characteristics of included
studies and Table 2 presents baseline demographic and clinical fea-
tures for all participants combined across different studies, including
details of the nature of cardiac surgery and treatment allocation prior
to operation. The majority of studies (8 of 11) used atorvastatin as
their intervention. The median duration of statin pretreatment
across all studies combined was 7 days (range 2–21 days).
Biomarkersof cardiacmuscle injurywerenormal atbaseline in all par-
ticipants as this was a mandatory requirement before proceeding to
surgery. All studies included statin-naive patients, except the study by
Kourliouros et al.,27 which enrolled participants receiving chronic,
low-dose statin therapy at baseline. People with severe renal
failure, or liver or muscle disease at baseline, were already excluded
from individual studies by virtue of their own design. Regardless of
their initial randomization (to statin or no statin pretreatment)
before surgery, all participants eventually received statin treatment
following surgery. There were no significant differences in the use
of perioperative anti-arrhythmic medications between the statin
and the control groups, with the exception of calcium antagonists
(higher among statin-treated individuals vs. controls, P ¼ 0.006).
Biases potentially affecting the results of the included studies are sum-
marized in Table 3.
Primary end point
Overall, 19% (105/552) of those who received statin pretreatment
vs. 36% (198/553) of those randomized to the control group devel-
oped postoperative, in-hospital AF. The use of statin treatment
prior to surgery was associated with 60% reduction in the risk of
incident AF among people undergoing cardiac surgery (OR 0.41,
95% CI 0.31–0.54; P, 0.00001; Figure 2), with little heterogeneity
between studies (P ¼ 0.95, I2 ¼ 0%). The clinical benefit of statin
pretreatment was qualitatively similar after excluding the study by
Kourliouros et al.,27 which enrolled patients on chronic statin therapy
at baseline (OR 0.38, 95% CI 0.28–0.51; P, 0.00001). Notably, the
effect of statin pretreatment was found to be consistent across
various participant subgroups with no evidence of effect modification
(Figure 3).
Other outcome measures
Pretreatment with statins was associated with a significant reduction
in perioperative myocardial injury (44 vs. 56%; P ¼ 0.007). No signifi-
cant adverse effects (such as elevation of transaminases or creatine
kinase elevation .3× ULN) were observed on statin pretreatment
in any study. The proportion of people who developed MACE
in-hospital following cardiac surgery was lower among those rando-
mized to statin pretreatment when compared with those within the
control group (1.3 vs. 2.4%, respectively), but this difference did not
achieve statistical significance (OR 0.53, 95% CI0.19–1.44;P ¼ 0.26).
Rates of in-hospital deaths and strokes were also lower (though non-
significant) in patients pretreated with statins when compared with
controls (0.2 vs. 0.5%, OR 0.33, 95% CI 0.01–3.57, P ¼ 0.31; 1.1 vs.
1.8%, OR 0.60, 95% CI 0.19–1.79, P ¼ 0.32, respectively).
Inflammation and statin efficacy
Randomization to statin therapy reduced preoperative hs-CRP levels
measured the day before surgery (1.14 mg/L, 0.78–2.10 mg/L vs.
1.26 mg/L, 0.90–2.25 mg/L in the control arm; P ¼ 0.01), with a
median of 1.2 mg/L (when both arms were combined). While pre-
operative hs-CRP levels were found to be higher among those who
subsequently developed postoperative AF (median 1.58 mg/L, inter-
quartile range 1.00–2.63 mg/L vs. 1.13 mg/L, 0.75–1.95 mg/L among
those who did not develop AF after surgery; P ¼ 0.0001), there was
no evidence of effect modification according to whether people had
higher- (OR 0.47, 95% CI 0.30–0.72) vs. lower- (OR 0.39, 95% CI
Statin pretreatment reduce the risk of AF 857
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Table 1 Characteristics of included studies
Study Year Number Regimen Duration
(days)
Age
(Mean)
Female,
n (%)
On-pump
surgery, n
(%)
CABG
only,n (%)
Hypertension,
n (%)
DM, n
(%)
CRF,n
(%)
COPD,
n (%)
Amiodarone
use, n (%)
Beta-blocker
use, n (%)
Calcium
antagonist
use, n (%)
ARMYDA-3 2006 200 Atorvastatin
40 mg
7 66.4 53 (27) 200 (100) 147 (74) 173 (87) 74 (37) 51 (26) 64 (32) 69 (35) 132 (66) 142 (71)
Baran 2011 60 Atorvastatin
40 mg
14 61.5 23 (38) 60 (100) 60 (100) 37 (62) 18 (30) 0 (0) 21 (35) 0 (0) 30 (50) 3 (5)
Berkan 2009 46 Fluvastatin
80 mg
21 66.5 17 (37) 46 (100) 46 (100) 16 (35) 17 (37) 0 (0) 16 (35) 0 (0) 46 (100) 0 (0)
Caorsi 2008 43 Pravastatin
40 mg
2 68.1 7 (16) 43 (100) 43(100) 33 (77) 17 (40) 0 (0) 0 (0) 0 (0) 15 (35) 10 (23)
Chello 2006 40 Atorvastatin
20 mg
21 64.7 9 (23) 40 (100) 40 (100) 18 (45) 0 (0) 0 (0) 15 (38) 0 (0) 13 (33) 14 (35)
Ji 2009 140 Atorvastatin
20 mg
7 65.8 43 (31) 0 (0) 140 (100) 41 (29) 53 (38) 0 (0) 45 (32) 0 (0) 87 (62) 71 (51)
Kourliouros 2011 102 Atorvastatin
80 mg
7 66.3 13 (13) 76 (75) 89 (87) 69 (68) 20 (20) 0 (0) 8 (8) 0 (0) 66 (65) 26 (25)
Mannacio 2008 200 Rosuvastatin
20 mg
7 60.3 55 (28) 200 (100) 200 (100) 46 (23) 0 (0) 7 (4) 44 (22) 22 (11) 141 (71) 57 (29)
Song 2008 124 Atorvastatin
20 mg
3 62.8 43 (35) 0 (0) 124 (100) 72 (58) 61 (49) 4 (3) NA 20 (16) 87 (70) 18 (15)
Spadaccio 2010 50 Atorvastatin
20 mg
21 66.3 23 (46) 50 (100) 34 (68) 25 (50) 0 (0) 0 (0) 5 (10) NA 14 (28) 12 (24)
Sun 2011 100 Atorvastatin
20 mg
7 64.7 33 (33) 100 (100) 100 (100) 31 (31) 38 (38) 0 (0) 31 (31) 0 (0) 62 (62) 51 (51)
Total 1105 64.4+2.6a 319 (29) 815 (74) 1023 (93) 561 (51) 298 (27) 62 (6) 249 (23) 111 (10) 693 (63) 404 (36)
CABG: coronary artery bypass graft; DM: diabetes mellitus; CRF: chronic renal failure; COPD: chronic obstructive pulmonary disease; NA: not available.
aWeighted mean.
G
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0.23–0.67)than-average hs-CRP concentrations preoperatively
(P-value for interaction ¼ 0.51).
Discussion
This collaborative meta-analysis of individual participant-level data
provides the most robust evidence to date that, among individuals
undergoing cardiac surgery, pretreatment with statins significantly
reduces the risk of postoperative AF by approximately two-thirds
compared with standard therapy. Moreover, this effect wasconsistent
across studies despite important differences in their design and charac-
teristics, including whether the cardiac surgery was ‘on-pump’ or
‘off-pump’, coronary or valvular, and regardless of background
anti-arrhythmic therapy.
Several factors have been incriminated in the development of AF
following cardiac surgery, as discussed elsewhere.4 Importantly,
advanced age and the need for valve surgery are recognized as risk
factors for postoperative AF because of haemodynamic, electrical
and histological abnormalities of the atrial tissue.2,40 Hence, despite
improvements in surgical techniques, the frequency of postoperative
AF appears to be increasing, likely due to increasing numbers of
elderly patients undergoing cardiac surgery,2 including valve surgery.
Postoperative AF has been shown to be associated with a higher
incidence of complications such as congestive heart failure, cerebro-
vascular accidents (nearly three-fold excess risk of stroke4), renal
dysfunction, infections, and neurological/cognitive impairment.2–4
Postoperative AF also increases the length of in-hospital stay, with
one study reporting an additional attributable cost of $6356 per
patient.41
Previous studies have suggested that patients on long-term statin
treatment who undergo cardiac surgery may have a lower risk of
early, in-hospital AF.12– 20 However, these were largely observation-
al, non-randomized studies based on participants having variable risk
profiles and treated with dissimilar protocols (e.g. use of statins at
variable doses and for variable lengths of time). Moreover, a longer-
term use of statin pretreatment in many studies meant that it was dif-
ficult to assess whether any arrhythmic protection was mediated by
lipid-lowering or non-lipid-lowering (i.e. pleiotropic) effects of
statins. Against this backdrop, there has been a recent surge in the
number of prospective, randomized controlled trials that studied
the effect of short-term statin treatment preoperatively on the risk
of postoperative AF in patients undergoing cardiac surgery.21 –31
These studies were individually underpowered, with some showing
a benefit21 –23,25,26,28– 31 andothers aneutral effect24,27 on the occur-
rence of postoperative AF. In this regard, Rahimi et al.42 in a large
meta-analysis of published and unpublished data found that there is
no evidence for AF prevention by longer-term treatment with
statins, whereas short-term treatment seems to reduce the odds of
anepisodeof AFby 39%, although therewas significant heterogeneity
between the trials included in their analysis.
While pooledanalyses of data frommultiple studies can help clarify
such uncertainties, important methodological limitations of these
approaches have hitherto led to biased estimates of association.
For instance, a previous meta-analysis had combined both observa-
tional and clinical trial data,43 and failed to show any significant reduc-
tion in risk of postoperative AF in people receiving statin therapy.
Although four further meta-analyses of randomized controlled
trials were published subsequently44 –47 and showed a beneficial
effect of statin pretreatment on postoperative AF, they were
limited by: the non-inclusion of all relevant studies; paucity of infor-
mation on key participant subgroups and/or outcomes (e.g. early
adverse cardiovascular events); and the use of aggregate (as
opposed to individual participant) data, precluding consistent analytic
approaches to be used across studies. We were therefore able to
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2 Main baseline characteristics in the overall
population
Characteristics Statin
pretreatment
(N 5 552)
Controls
(N5 553)
P-value
Age (years) 64.2+8.7 64.6+8.8 0.45
Female sex 148 (27) 154 (28) 0.76
Systemic hypertension 298 (54) 266 (48) 0.06
Diabetes mellitus 145 (26) 166 (30) 0.19
Chronic renal failure 34 (6) 33 (6) 0.99
Chronic obstructive
pulmonary disease
114 (21) 135 (24) 0.16
Body mass index (kg/m2) 25.6+2.4 25.7+2.6 0.51
Type of operation
CABG 522 (95) 502 (91) 0.017
CABG + valvular 11 (2) 8 (1) 0.64
Valvular/ascending aorta 19 (3) 44 (8) 0.002
On-pump surgery 405 (73) 410 (74) 0.76
Previous atrial fibrillation 16 (3) 28 (5) 0.09
Left ventricular ejection
fraction ,60%
304 (55) 320 (58) 0.40
Medical therapy
Use of amiodarone 52 (9) 59 (11) 0.56
Use of beta-blockers 358 (65) 335 (60) 0.14
Use of calcium
antagonists
224 (40) 180 (32) 0.006
Values are given as number of patients (%) or mean+ SD.
CABG: coronary artery bypass graft; CRP: C-reactive protein.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 3 Potential sources of bias in included studies
Study Possible sources of bias
Baran No definition of postoperative AF available
Berkan Open-label randomized trial
No definition of postoperative AF available
Incidence of postoperative AF not published
Caorsi Open-label randomized trial
Kourliouros Single-blind randomized trial
Patients previously on low-dose statin therapy
Mannacio No definition of postoperative AF available
Song Open-label
No placebo-controlled study
Spadaccio No definition of postoperative AF available
Statin pretreatment reduce the risk of AF 859
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overcome these limitations by conducting an individual–participant
data meta-analysis of all relevant randomized clinical trials. Our find-
ings suggest that, in populations having a similar baseline risk of post-
operative AF, approximately six people would require statin
pretreatment for an average of 7 days before cardiac surgery to
prevent one incident event of AF. The reduction in postoperative
AF was independent of the patient characteristics including age,
gender, presence of diabetes, and other comorbidities as well as sur-
gical techniques. In fact, the relative risk reduction of postoperative
AF was identical (58%) for on-pump vs. off-pump coronary surgery.
Moreover, given the observation that preoperative statin therapy
was associated with a significant reduction in perioperative myocar-
dial injury without a concomitant increase in statin-related adverse
effects (such as elevation of transaminases or creatine kinase), it is
possible that the net clinical benefit of statins may be even higher
than what was shown in our analysis.
Despite robust statistical evidence, the underlying mechanisms
that may mediate this beneficial effect of statins on AF remain
poorly understood. We pre-selected studies that had used short-
term statin treatment before cardiac surgery (median 7 days) to
minimize the impact of more long-term changes in cholesterol con-
centrations on clinical outcomes and to help contextualize the role of
potential ‘pleiotropic effects’ of statins, although previous studies
have questioned the clinical impact of those ‘pleiotropic effects’ in
preventing cardiac arrhythmias.48 It has been hypothesized that in-
flammatory mechanisms may be involved in the pathogenesis of AF
after cardiac surgery,5– 7 with evidence suggesting that cytokine
release, leucocyte–endothelial adhesion, and levels of circulating ad-
hesion molecules after cardiac surgery are reduced in patients receiv-
ing statin therapy.25,49,50 While, in our meta-analysis, we not only
observed that preoperative CRP levels were higher among partici-
pants who developed postoperative AF, statin pretreatment also
resulted in a significant attenuation of preoperative CRP levels.
However, there was no differential benefit of statin therapy among
those with hs-CRP levels above or below the median. While these
data suggest that inflammation may be a determinant of postoperative
AF, they do not provide definitive evidence that suppression of inflam-
mation by statin therapy mitigates the risk of this condition. Other
postulated mechanisms that may contribute to the anti-arrhythmic
benefit of statins include antioxidant51 and direct anti-arrhythmic
effects by cell membrane ion channel stabilization.52 It has been
shown that biomarkers of cardiac muscle injury may be elevated
aftercardiac surgery inupto60%ofpatients.38Thishasbeenattributed
to factors such as myocardial injury from aortic cross clamping and re-
sultant global ischaemia/reperfusion injury; inflammatory response
associatedwithprolongedcardiopulmonarybypass; hypothermia; sur-
gical trauma; and intramyocardial vessel manipulation.53,54 In keeping
with previous small-scale,28,55–57 mainly retrospective55 evidence,
we prospectively found a significant reduction in perioperative myo-
cardial injury (albeit not accompaniedbyclinicalevidenceof ischaemia)
onstatin therapy,whichmayhavecontributed to the lowerriskofAF.58
While the benefits of statin therapy on myocardial ischaemia may
be related to lipid-lowering effects and plaque stabilization, other
mechanisms have also been suggested including ischaemic precondi-
tioning via activation of nitric oxide synthase and promotion of
cyclooxygenase-2 and prostaglandin I2.59,60
Despite notable strengths (increased power, consistent analytical
approaches across studies), there are nonetheless some limitations
to our meta-analysis. First, we did not include studies that were not
published in English language, and were moreover unable to obtain
participant-level data from two further trials that met our inclusion
criteria. Although this may have improved the power and precision
of our analyses, it is unlikely to have materially altered the overall
associations studied, since we were able to include the majority of
relevant randomized trials in our meta-analysis. Secondly, despite
combining data from multiple studies, it is possible that the observed
associations are still spurious (and related to potential publication
bias) since individually, the trials included in our meta-analysis were
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Figure 2 Meta-analysis of the effect of statin pretreatment on postoperative atrial fibrillation.
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Figure 3 Effect of statin pretreatment on postoperative atrial fibrillation in subgroups of participants.
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small in size. This is especially relevant in the context of subgroup-
specific associations, where further study is needed to identify
strata of individuals at higher-than-average risk of developing post-
operative AF. This is especially relevant given emerging evidence
from single, large, well-powered randomized controlled trials that
suggest no obvious benefit of perioperative statin use in preventing
postoperative AF (i.e. perioperative statin treatment in cardiac
surgery for the prevention of AF and perioperative myocardial
damage: the Statin Therapy In Cardiac Surgery [STICS] Trial pre-
sented at the Annual Congressof the European Societyof Cardiology
2014, Barcelona). Thirdly, the definition of AF (as well as other end
points) varied across trials, which may have led to systematic over-
or underestimation of the observed associations. Nevertheless, as
between-study heterogeneity was remarkably low, this is unlikely
to have materially altered our findings. Fourthly, it is also possible
that a proportion of individuals may have experienced subclinical
and/or symptomatic, yet undocumented, AF episodes prior to their
cardiac surgery. Since more subjects within the control group under-
went valvular heart surgery, the prevalence of pre-existing AF may
have been substantially higher in this group, leading to some overesti-
mation of the benefit of statins. However, the lack of any statistically
significant interaction based on the type of cardiac surgery (i.e. valvu-
lar vs. non-valvular), though ecological, suggests that the influence of
any unequal distribution of baseline AF between the two treatment
groups may not have had a substantial effect on the overall associa-
tions. Fifthly, individual studies differed with regard to the type and
dose of statin medication used prior to cardiac surgery, and therefore
further investigations are needed to identify the optimum dose of
statin medication for the prevention of postoperative AF. Sixthly,
we did not have access to long-term follow-up data from individual
studies and were therefore unable to confirm (or refute) any
legacy effects of ‘short-course’ statin treatment preoperatively.
Seventhly, as the majority of participants contributing to this
meta-analysis underwent coronary artery bypass graft surgery
(CABG), it is possible that (despite meticulous care to include statin-
naive individuals only in our analyses) a proportion of them may have
been prescribed long-term statin therapy, leading to potential over-
estimation of the observed associations. Nonetheless, we believe
that our findings are clinically relevant, because they reaffirm the
importance of initiation of and compliance with statin therapy pre-
operatively before cardiac surgery, including (and perhaps more
so) in the context of non-CABG-related cardiac surgery. Eighthly,
it is possible that the beneficial effect of preoperative statin use
may have been somewhat overestimated due to the slightly higher
prevalence (at baseline) of individuals with prior AF in the control
group. However, it is reassuring that these differences were not
statistically significant and therefore were unlikely to have had
any major impact on the overall associations. Ninthly, since the use
of calcium antagonists was significantly higher among statin-treated
individuals, adequate rate control provided by these agents may
have led to under-reporting of AF episodes postoperatively,
thereby leading to potential overestimation of statin benefit. Finally,
as the majority of studies used atorvastatin as their active treatment
and since most involved participants from developed countries,
it is uncertain whether the results of this meta-analysis would
equally apply to other statin medications or diverse populations,
respectively.
Conclusions
In conclusion, using the largest available evidence to date and
by applying systematic approaches to harmonizing and analysing
participant-level data, we were able to demonstrate a significant
benefit of short-term statin pretreatment before planned cardiac
surgery on the risk of postoperative AF. These effects could support
a potential pleiotropic role for statins in arrhythmia suppression
postoperatively among people undergoing cardiac surgery, over and
above their well-established long-term effects on atherosclerosis-/
cholesterol-mediated vascular risk, although further studies are
warranted to establish with certainty whether the benefit is equally
applicable to all statin subtypes (STICS Trial presented at the Annual
Congress of the European Society of Cardiology 2014, Barcelona).
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